Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TYK2: An Upstream Kinase of STATs in Cancer
Katharina Wöss, Natalija Simonović, Birgit Strobl, et al.
Cancers (2019) Vol. 11, Iss. 11, pp. 1728-1728
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Importance of STAT3 signalling in cancer, metastasis and therapeutic interventions
Mohamed El‐Tanani, Arwa Omar Al Khatib, Safwan Aladwan, et al.
Cellular Signalling (2022) Vol. 92, pp. 110275-110275
Open Access | Times Cited: 64
Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors
Lise T. Jensen, Kathrine E. Attfield, Marc Feldmann, et al.
EBioMedicine (2023) Vol. 97, pp. 104840-104840
Open Access | Times Cited: 31
Janus Kinases in Leukemia
Juuli Raivola, T. Haikarainen, Bobin George Abraham, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 800-800
Open Access | Times Cited: 41
Identifying common transcriptome signatures of cancer by interpreting deep learning models
Anupama Jha, Mathieu Quesnel-Vallières, David Wang, et al.
Genome biology (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 30
Heat-Shock Proteins in Leukemia and Lymphoma: Multitargets for Innovative Therapeutic Approaches
Vincent Cabaud Gibouin, Manon Durand, Ronan Quéré, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 984-984
Open Access | Times Cited: 20
Cross-Talk between Receptor Tyrosine Kinases AXL and ERBB3 Regulates Invadopodia Formation in Melanoma Cells
Or‐Yam Revach, Oded Sandler, Yardena Samuels, et al.
Cancer Research (2019) Vol. 79, Iss. 10, pp. 2634-2648
Open Access | Times Cited: 47
Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer
Al‐Hassan M. Mustafa, Oliver H. Krämer
Pharmacological Reviews (2022) Vol. 75, Iss. 1, pp. 35-61
Closed Access | Times Cited: 22
Dual inhibition of JAK3 and PD-L1 boosts immune response in triple negative breast cancer
Huali Xiang, Binfeng Tu, Xin Feng, et al.
Anti-Cancer Drugs (2025)
Closed Access
Cell-type-specific requirement for TYK2 in murine immune cells under steady state and challenged conditions
Anzhelika Karjalainen, Agnieszka Witalisz‐Siepracka, Michaela Prchal‐Murphy, et al.
Cellular and Molecular Life Sciences (2025) Vol. 82, Iss. 1
Open Access
<p>Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis</p>
Rhea Singh, Courtney E. Heron, Rima I. Ghamrawi, et al.
ImmunoTargets and Therapy (2020) Vol. Volume 9, pp. 255-272
Open Access | Times Cited: 37
Synthesis and biological evaluation of new tri-heterocyclic derivatives as anti-colorectal cancer agents
Benjamin Victoir, Océane Pertegaz, Elfi Ducrocq, et al.
Results in Chemistry (2025) Vol. 13, pp. 102015-102015
Open Access
Malignant JAK-signaling: at the interface of inflammation and malignant transformation
Florian Perner, Heike L. Pahl, Robert Zeiser, et al.
Leukemia (2025)
Open Access
Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities
Shan Wang, Rong‐Hong Zhang, Hong Zhang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 222, pp. 113573-113573
Closed Access | Times Cited: 25
TYK2 in Cancer Metastases: Genomic and Proteomic Discovery
Dana C. Borcherding, Kevin He, Neha V. Amin, et al.
Cancers (2021) Vol. 13, Iss. 16, pp. 4171-4171
Open Access | Times Cited: 25
The Function of N-Myc Downstream-Regulated Gene 2 (NDRG2) as a Negative Regulator in Tumor Cell Metastasis
Ki Won Lee, Seyeon Lim, Kwang Dong Kim
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9365-9365
Open Access | Times Cited: 17
Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors
Kuojun Zhang, Ke Ye, He Tang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 4378-4416
Closed Access | Times Cited: 10
TYK2 in Tumor Immunosurveillance
Anzhelika Karjalainen, Stephen Shoebridge, Milica Krunic, et al.
Cancers (2020) Vol. 12, Iss. 1, pp. 150-150
Open Access | Times Cited: 26
Translating current basic research into future therapies for neurofibromatosis type 1
Jean‐Philippe Brosseau, Chung-Ping Liao, Lu Q. Le
British Journal of Cancer (2020) Vol. 123, Iss. 2, pp. 178-186
Open Access | Times Cited: 22
Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting
Sreedhar Amere Subbarao
Inflammopharmacology (2021) Vol. 29, Iss. 2, pp. 343-366
Open Access | Times Cited: 19
Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies?
Klara R. Klein, Dagmar Stoiber, Veronika Sexl, et al.
Cancers (2021) Vol. 13, Iss. 11, pp. 2611-2611
Open Access | Times Cited: 19
From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases
Dominika Hromadová, Dirk Elewaut, Robert D. Inman, et al.
Frontiers in Genetics (2021) Vol. 12
Open Access | Times Cited: 19
Targeting TYK2 alleviates Rab27A-induced malignant progression of non-small cell lung cancer via disrupting IFNα-TYK2-STAT-HSPA5 axis
Yuanyuan Zeng, Jian Zhao, Zhengyan Wu, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 2
Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors
George Βertsias
Mediterranean Journal of Rheumatology (2020) Vol. 31, Iss. Suppl 1, pp. 105-105
Open Access | Times Cited: 20
IL22RA1/JAK/STAT Signaling Acts As a Cancer Target Through Pan-Cancer Analysis
Shuai Zhang, Guiyan Yang
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
STAT3 signaling in pancreatic ductal adenocarcinoma: a candidate therapeutic target
Hussein Riyadh Abdul Kareem Al‐Hetty, Sada Jasim Abdulameer, Sami Awad Alkubaisy, et al.
Pathology - Research and Practice (2023) Vol. 245, pp. 154425-154425
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top